Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SHP2 is a protein tyrosine phosphatase that promotes RAS signaling through multiple mechanisms, including facilitation of SOS1-mediated nucleotide exchange and regulation of KRAS conformational dynamics through dephosphorylation of Tyr32 and Tyr64 [8,9].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Src homology region 2 domain-containing phosphatase 2 (SHP2) is a receptor-free protein-tyrosine phosphatase and regulates proliferation by activating the RAS–MAPK–ERK signaling pathway.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1983 · Cited by 221
RetractedRETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., & Cheng, S. (2011) · Oncogene · doi:10.1038/onc.2011.436 · Cited by 78
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citationThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
The Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Research works printed but not linked: 1
- Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“While the direct pharmacological inhibition of RAS is still being explored, alternative approaches to targeting RAS regulators such as PHLPP, SHP-2, and NF-2 have also been proposed [162,169,170].”
BackgroundKRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C.-Y., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 216
Huang, J.-L., Jiang, G., Song, Q.-X., Gu, X., Hu, M., Wang, X.-L., Song, H.-H., Chen, L.-P., Lin, Y.-Y., Jiang, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 209
“It was reported that in glioblastoma, the wild-type Ras is hyperactivated, and the high expression of Ras combined with Akt mediates glioblastoma formation 37–39 .”
Targeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
“PTPN11 encodes for the protein tyrosine phosphatase SHP2 that dephosphorylates Y32, thus activating RAS proteins [254].”
BackgroundDrugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases
Zhang, Z.-Y. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00537 · Cited by 182
Self-citationTherapeutic targeting of oncogenic tyrosine phosphatases
Frankson, R., Yu, Z.-H., Bai, Y., Li, Q., Zhang, R.-Y., & Zhang, Z.-Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1510 · Cited by 189
“Most recent data indicate that dephosphorylation of Ras/pTyr32 by SHP2 can also lead to Ras activation (5).”
BackgroundSelf-citationRAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
“In the context of RAF or MEK inhibition, YAP1, a component of the Hippo pathway, promoted survival of RAS-mutant cells, with combinatorial inhibition of MEK and YAP1 yielding improved therapeutic efficacy (136).”
BackgroundInfluentialDiscovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172
Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
Bollu, L. R., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0934 · Cited by 168
“Similarly, Bunda and colleagues have shown that pharmacologic inhibition of SHP2 by a salicylic acid–based SHP2 inhibitor attenuates growth and progression of gliomas (34, 58).”
BackgroundDual Allosteric Inhibition of SHP2 Phosphatase
Fodor, M., Price, E., Wang, P., Lu, H., Argintaru, A., Chen, Z., Glick, M., Hao, H.-X., Kato, M., Koenig, R., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00980 · Cited by 126
“In 2015, SHP2 was reported to bind and dephosphorylate RAS, increase RAS– RAF association, and activate downstream proliferative RAS/ERK/MAPK signaling.(12) SHP2”
BackgroundRegulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases
Yu, Z.-H., & Zhang, Z.-Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00105 · Cited by 124
Self-citationSong, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Therapeutic targeting of RAS: New hope for drugging the “undruggable”
Khan, I., Rhett, J. M., & O'Bryan, J. P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 110
Vainonen, J. P., Momeny, M., & Westermarck, J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 104
“In two studies from the Ohh laboratory, SHP2 was found to directly bind and dephosphorylate K-, N-, and H-RAS in cultured cells (29, 30).”
BackgroundTyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103
Self-citationTargeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 94
“can suppress tumor growth in multiple cancers (Bunda et al., 2015; Mainardi et al., 2018; Wong et al., 2018).”
Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
Bagdanoff, J. T., Chen, Z., Acker, M., Chen, Y.-N., Chan, H., Dore, M., Firestone, B., Fodor, M., Fortanet, J., Hentemann, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01725 · Cited by 84
Dynamic regulation of RAS and RAS signaling
Kölch, W., Berta, D., & Rosta, E. (2023) · Biochemical Journal · doi:10.1042/bcj20220234 · Cited by 104
Choi, S., Warzecha, C. C., Zvezdova, E., Lee, J., Argenty, J., Lesourne, R., Aravind, L., & Love, P. E. (2017) · Nature Immunology · doi:10.1038/ni.3692 · Cited by 95
Turning the tide in myelodysplastic/myeloproliferative neoplasms
Deininger, M. W., Tyner, J. W., & Solary, É. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.40 · Cited by 95
CIC protein instability contributes to tumorigenesis in glioblastoma
Bunda, S., Heir, P., Metcalf, J. L., Li, A. S. C., Agnihotri, S., Pusch, S., Mamatjan, Y., Li, M., Burrell, K. E., Mansouri, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08087-9 · Cited by 97
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01818-1 · Cited by 86
Self-citationTargeting endogenous proteins for degradation through the affinity-directed protein missile system
Fulcher, L. J., Hutchinson, L. D., Macartney, T. J., Turnbull, C., & Sapkota, G. P. (2017) · Open Biology · doi:10.1098/rsob.170066 · Cited by 79
Post-translational modification of RAS proteins
Campbell, S. L., & Philips, M. R. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.06.015 · Cited by 72
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
“The dephosphorylation of Y32 is mediated by the phosphatase SHP2, which directly activates RAS downstream of RTK signaling [81].”
BackgroundWei, Q., Singh, O., Ekinci, C., Gill, J. K., Li, M., Mamatjan, Y., Karimi, S., Bunda, S., Mansouri, S., Aldape, K., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01163-0 · Cited by 70
“Upregulation of VCAM1 and ICAM1 on ECs has been shown to promote further recruitment and attachment of monocytes to the blood vessel wall where they can then migrate into the brain parenchyma, differentiate into macrophages, and exacerbate a GAM-induced inflammatory response [6, 26, 41].”
BackgroundMethodSelf-citationSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
“Furthermore, SHP2 can activate KRAS through dephosphorylation of some regulatory molecules, including p120GAP (19,31,32).”
BackgroundPatel, Y. K., Shah, N. R., Lee, J. S., Markoutsa, E., Jie, C., Liu, S., Botbyl, R., Reisman, D., Xu, P., & Chen, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7577 · Cited by 66
“SHP-2 is known to affect ERK signaling [28, 29].”
BackgroundZhang, K., Myllymäki, S.-M., Gao, P., Devarajan, R., Kytölä, V, Nykter, M., Wei, G.-H., & Manninen, A. (2017) · Oncogene · doi:10.1038/onc.2017.177 · Cited by 66
Stopping the beating heart of cancer: KRAS reviewed
Herdeis, L., Gerlach, D., McConnell, D. B., & Kessler, D. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.06.013 · Cited by 62
The Molecular Genetics of Myeloproliferative Neoplasms
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 69
“Protein tyrosine phosphatase, nonreceptor type 11 (PTPN11) is a protein tyrosine phosphatase that acts downstream from several transmembrane receptors and dephosphorylates RAS (Bunda et al. 2015).”
BackgroundInfluentialSHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Chen, H., Libring, S., Ruddraraju, K. V., Miao, J., Solorio, L., Zhang, Z., & Wendt, M. K. (2020) · Oncogene · doi:10.1038/s41388-020-01488-5 · Cited by 68
Self-citationTargeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure
Haugh, A. M., Zhang, B., Quan, V. L., Garfield, E. M., Bubley, J. A., Kudalkar, E. M., Verzì, A. E., Walton, K. E., VandenBoom, T. G., Merkel, E. A., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.08.022 · Cited by 67
“Activating mutations in PTNP11 lead to constitutive activation of its protein product, Shp2, which directly activates the MAPK pathway (Bunda et al., 2015).”
BackgroundPresotto, D., Erdes, E., Duong, M. N., Allard, M., Regamey, P.-O., Quadroni, M., Doucey, M.-A., Rufer, N., & Hebeisen, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01564 · Cited by 63
“Our results are also in agreement with the reported positive role of SHP-2 in promoting ERK1/2 activation (21, 54, 55), although this was not directly related to the TCR affinity-dependent increase in pSHP-2 (Y542 and Y580) levels observed after TCR-specific triggering (Figure 5).”
ResultSphingosine 1-Phosphate (S1P) Signaling in Glioblastoma Multiforme—A Systematic Review
Mahajan, S. G., Bien-Möller, S., Marx, S., Schroeder, H. W. S., & Rauch, B. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112448 · Cited by 65
“Another enzyme molecule is SHP-2 (Src homology-2 domain-containing phosphatase)—a ubiquitously expressed tyrosine phosphatase—which was shown to preferentially bind to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signaling in a mouse model of GBM [48].”
BackgroundValencia-Sama, I., Ladumor, Y., Kee, L., Adderley, T., Christopher, G., Robinson, C. M., Kano, Y., Ohh, M., & Irwin, M. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3822 · Cited by 62
Self-citationThe Ins and Outs of RAS Effector Complexes
Kiel, C., Matallanas, D., & Kölch, W. (2021) · Biomolecules · doi:10.3390/biom11020236 · Cited by 63
“New efforts targeting regulators of RAS modifications, such as SHP-2, are being explored [80,83], but it remains to be seen how effective they may be in blocking mutant RAS proteins.”
BackgroundChitranshi, N., Dheer, Y., Mirzaei, M., Wu, Y., Salekdeh, G. H., Abbasi, M., Gupta, V. B., Wall, R. V., You, Y., Graham, S. L., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.019 · Cited by 60
“This negative modulation of PI3K downstream signaling in the retinal tissue by Shp2 is a novel observation and is in contrast to the effects of Shp2 inhibition reported previously in CD34 cells and other tumor tissues.(54,55) Shp2 was shown to negatively affect PI3K/ Akt activation induced by epidermal growth factor t…”
ResultSHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
Niogret, C., Birchmeier, W., & Guarda, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02468 · Cited by 58
“Second, RAS tyrosine phosphorylation at position 32 negatively impacts on downstream signaling, possibly by favoring the interaction with RAS-GAP; by removing this modification, SHP-2 promotes ERK activation (Figure 2B) (52).”
BackgroundSignal transduction pathways and resistance to targeted therapies in glioma
Tomiyama, A., & Ichimura, K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.004 · Cited by 56
Siglecs as Therapeutic Targets in Cancer
Lim, J., Sari-Ak, D., & Bagga, T. (2021) · Biology · doi:10.3390/biology10111178 · Cited by 50
Gebregiworgis, T., Kano, Y., St-Germain, J., Radulovich, N., Udaskin, M. L., Mentes, A., Huang, R., Poon, B. P. K., He, W., Valencia-Sama, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26526-y · Cited by 49
“RAS/RAF binding was assessed using the RAS activation assay kit from Millipore (17-218).”
MethodSelf-citationPancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 64
“215,220 In this context, SFK inhibitors can induce RAS hyperactivation, thereby leading to enhanced RAF/MEK/ERK signaling in PDAC cells.”
InfluentialUniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 50
“Modifications in the KRAS proteins are carried out via mutations to restrict KRAS from interacting with GAPs, including the hydrolyzing GTP linked with KRAS, keeping KRAS in a constantly activated state [58,59].”
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Hill, K. S., Roberts, E. R., Wang, X., Marin, E. M., Park, T. D., Son, S., Ren, Y., Fang, B., Yoder, S., Kim, S., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0777 · Cited by 51
“A recent study by Bunda and colleagues showed dephosphorylation and activation of Ras by PTPN11 (17).”
BackgroundTang, K., Jia, Y.-N., Yu, B., & Liu, H.-M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112657 · Cited by 45
Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors
Kong, J., & Long, Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d1md00386k · Cited by 47
An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer
Robinson, C. M., Talty, A., Logue, S. E., Mnich, K., Gorman, A. M., & Samali, A. (2021) · Cancers · doi:10.3390/cancers13020261 · Cited by 46
“Small molecule inhibitors that directly target KRASG12C, as well as the development of inhibitors of Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2), a non-receptor protein tyrosine phosphatase that modulates RAS activity [10,11], have yielded promising pre-clinical results, although their clini…”
BackgroundResistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cremer, A., Ellegast, J. M., Alexe, G., Frank, E. S., Ross, L. S., Chu, S. H., Pikman, Y., Robichaud, A. L., Goodale, A. B., Häupl, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0209 · Cited by 43
“Furthermore, SHP2 was identified as a direct activator of RAS and a potential target for cancers driven by hyperactive or oncogenic RAS (61).”
BackgroundChen, C., Liang, F., Chen, B., Sun, Z., Xue, T., Yang, R., & Luo, D. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.12.012 · Cited by 42
Vemulapalli, V., Chylek, L. A., Erickson, A. R., Pfeiffer, A., Gabriel, K.-H., LaRochelle, J. R., Subramanian, K., Cao, R., Stegmaier, K., Mohseni, M., et al. (2021) · eLife · doi:10.7554/elife.64251 · Cited by 44
“Genetic and mutational studies have implicated specific pY residues on RTKs as putative SHP2 substrates (Agazie and Hayman, 2003; Bunda et al., 2015; Klinghoffer and Kazlauskas, 1995).”
BackgroundStepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases
Elson, A. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.09.013 · Cited by 40
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy
Chou, S., Yen, S., Huang, C., & Huang, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-4025-2 · Cited by 39
Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
Qiu, Y., Wang, Y., Chai, Z., Ni, D., Li, X., Pu, J., Chen, J., Zhang, J., Lu, S., Lv, C., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.014 · Cited by 40
“Bunda et al.(62) determined that SHP2 functions as a direct activator of H/N-RAS by dephosphorylation of Tyr32, thus restoring the binding of RAF and resuscitating the downstream signaling.”
BackgroundTargeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 45
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
“Recently, Shp2 was shown to dephosphorylate and activate Ras[70].”
BackgroundSelf-citationTyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
Chen, X., Keller, S. J., Hafner, P., Alrawashdeh, A. Y., Avery, T. Y., Norona, J., Zhou, J., & Ruess, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340726 · Cited by 52
“In conclusion, selective and careful targeting of SHP2 may have therapeutic implications for the treatment of GBM, given the functional involvement of SHP2 in the onset and progression of the illness.”
BackgroundInfluentialNew Approaches to Difficult Drug Targets: The Phosphatase Story
Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 42
“Mechanistically, SHP2 appears to regulate numerous intracellular oncogenic signaling pathways, such as RASERK, PI3K-AKT, and JAK-STAT, at least in part by its ability to bind and dephosphorylate RAS.(64) This attractive drug target has been interrogated by traditional high-throughput and computational screens, yieldin…”
BackgroundTargeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症:英文版 · doi:10.1002/cac2.12377 · Cited by 39
“SHP2 can dephosphorylate tyrosine in RAS, thus restoring the downstream signaling and GTPase cycling [79, 80].”
BackgroundTargeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2–mediated signaling
Sang, Y., Hou, Y., Cheng, R., Zheng, L., Alvarez, A. A., Hu, B., Cheng, S., Zhang, W., Li, Y., & Feng, H. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz107 · Cited by 39
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Guijarro-Hernández, A., & Vizmanos, J. L. (2021) · Cancers · doi:10.3390/cancers13050984 · Cited by 44
Zhao, L., Xia, J., Li, T., Zhou, H., Ouyang, W., Hong, Z., Ke, Y., Qian, J., & Xu, F. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw205 · Cited by 36
Liu, Z., Zhao, Y. Q., Fang, J., Cui, R., Xiao, Y., & Xu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.18591 · Cited by 37
“SHP2 also is a negative factor in the activation of STAT1 phosphorylation [12] and a positive factor in the activation of extracellular signal regulated kinase (ERK) phosphorylation [13].”
BackgroundSmall molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Schlicher, L., Green, L. G., Romagnani, A., & Renner, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297175 · Cited by 35
Charette, M. E., Rosenblum, C., Shade, O., & Deiters, A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00224 · Cited by 37
Wang, W., Chen, X., Ya, G., Gao, L., Li, S., Zhu, J., Xu, L., Ding, Z.-Z., Zhang, C., Li, J., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.059 · Cited by 33
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 36
RAS pathway regulation in melanoma
Mahi, A. A., & Ablain, J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049229 · Cited by 38
Wang, J., Calizo, A., Zhang, L., Pino, J. C., Lyu, Y., Pollard, K., Zhang, X., Larsson, A. T., Conniff, E., Llosa, N. J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg8876 · Cited by 38
“SHP2 phosphatase also acts as a positive regulator of RAS by dephosphorylating RAS and promoting its binding to and activation of RAF kinases, leading to increased ERK signaling ( 27 ).”
BackgroundBhattacharyya, S., Feferman, L., & Tobacman, J. K. (2017) · Oncotarget · doi:10.18632/oncotarget.22152 · Cited by 35
“Previous reports of proto-oncogenic effects of SHP2 and the benefits of SHP2 inhibition may be confounded by the use of vanadate [34, 49], since vanadate also inhibits sulfatase activity [50, 51].”
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
“Firstly, as a tyrosine phosphatase that directly acts on RAS family members, favoring the dephosphorylated (active) form of RAS [56,60] and secondly, as a scaffold that facilitates the recruitment of GRB2-SOS to phosphorylated tyrosine residues in receptors and/or scaffolds at the plasma membrane, thereby promoting SO…”
BackgroundInfluentialTargeting SHP2 phosphatase in hematological malignancies
Kanumuri, R., Pasupuleti, S. K., Burns, S. S., Ramdas, B., & Kapur, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066518 · Cited by 31
“It can also dephosphorylate KRAS, NRAS, and HRAS in vitro and can indirectly regulate the activation of Ras through Src family kinases (SFKs) [15,45].”
BackgroundNovel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation
Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09918-2 · Cited by 31
Inhibition of SHP2 as an approach to block RAS-driven cancers
Chou, Y., & Bivona, T. G. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.002 · Cited by 33
Biology, pathology, and therapeutic targeting of RAS
Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 31
“GTP-loaded HRAS and NRAS reoriented to interact with the membrane through their α4 and α5 helices while activated KRAS remained more flexible (Gorfe et al., 2007; Kapoor, et al., 2012).”
BackgroundInfluentialLi, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 32
“SHP2 is a primary effector of receptor tyrosine kinase signaling, which dephosphorylates Ras and results in increased RaseRaf association and activation of downstream MAPK signaling.(72) In this scenario, the RTKassociated phosphatase SHP2 may represent a common target to inhibit feedback reactivation of multiple RTKs…”
BackgroundDavis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27584-x · Cited by 27
Chen, X., Shu, C., Li, W., Hou, Q., Luo, G., Yang, K., & Wu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00063 · Cited by 27
Rai, B., Naylor, P. E., Sanchez, M. S., Wintermark, M., Raman, M. M., Jo, B., Reiss, A. L., & Green, T. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02504-4 · Cited by 29
“PTPN11 variants constitutively activate SHP2, leading to downstream upregulation of the Ras-MAPK cascade [3, 6].”
BackgroundProtein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma
Ruckert, M. T., de Andrade, P. V., Santos, V. S., & Silveira, V. S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03095-4 · Cited by 28
Therapeutic targeting of p90 ribosomal S6 kinase
Wright, E. B., & Lannigan, D. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1297292 · Cited by 26
Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules
Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 26
Bhattacharyya, S., Feferman, L., Han, X., Ouyang, Y., Zhang, F., Linhardt, R. J., & Tobacman, J. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001244 · Cited by 26
Jiang, Z., van Vlimmeren, A. E., Karandur, D., Semmelman, A., & Shah, N. H. (2025) · Nature Communications · doi:10.1038/s41467-025-60641-4 · Cited by 29
“First, we examined the ability of the SHP2 mutants to depho-sphorylate N-Ras that has been phosphorylated by co-expressed Src kinase 54 .”
Coulombe, G., Langlois, A., Palma, G. D., Langlois, M., McCarville, J. L., Sansfaçon, J. G., Perreault, N., Feng, G., Berčík, P., Boudreau, F., et al. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25407 · Cited by 30
“SHP-2 also prefers the acidic residue aspartic acid (D) at pY −2 position with no basic residue on the C-terminal side (Ren et al., 2011; Bunda et al., 2015).”
Liu, Y., Zhang, W., Jang, H., & Nussinov, R. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05052-8 · Cited by 29
“It can dephosphorylate RTKs, and tyrosyl phosphorylated Ras at Y32 and Y64, which is required for the (re)activation of Ras and the Ras GTPase cycle [11–14].”
BackgroundDias, M. H., Liudkovska, V., Navarro, J. M., Giebel, L., Champagne, J., Papagianni, C., Bleijerveld, O. B., Velds, A., Agami, R., Bernards, R., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00128-3 · Cited by 26
Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment
Ma, C., Kang, D., Gao, P., Zhang, W., Wu, X.-P., Xu, Z., Han, H., Zhang, L., Cai, Y., Wang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00360 · Cited by 28
Sansfaçon, J. G., Coulombe, G., Langlois, M., Langlois, A., Paquet, M., Carrier, J. C., Feng, G., Qu, C., & Rivard, N. (2016) · Oncotarget · doi:10.18632/oncotarget.11601 · Cited by 27
“Recent results have further demonstrated that SHP-2 binds and dephosphorylates both wild-type and oncogenic HRAS on Tyr32 in astrocytes and glioma cells, an event that increases RAS association with RAF-1 and downstream MEK/ERK activation [48].”
ResultYuan, Y., Qi, G., Shen, H., Guo, A., Cao, F., Zhu, Y., Xiao, C., Chang, W., & Zheng, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31736 · Cited by 27
Dong, L., Han, D. W., Meng, X., Xu, M., Zheng, C., & Qin, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630712 · Cited by 25
“SHP2 activity is elevated by pathological analysis of astrocytes isolated from GBM. Patient-derived GBM specimens exhibit hyperactive Ras, while inhibition of SHP2 decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model (Bunda et al., 2015).”
BackgroundPan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Coley, A. B., Ward, A., Keeton, A. B., Chen, X., Maxuitenko, Y. Y., Prakash, A., Li, F., Foote, J. B., Buchsbaum, D. J., & Piazza, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.009 · Cited by 27
Metadata
- Authors
- Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Ohh, Michael
- Venue
- Nature Communications
- Published
- 2015-11-30
- Volume
- 6
- Issue
- 1
- Pages
- 8859-8859
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4674766
- OpenAlex
- W2254051095
- Cited by
- 249
- References
- 63
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 29 · 2023: 36 · 2022: 30 · 2021: 30 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 21 · 2016: 10
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA69202, R01CA069202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- SHP2, protein tyrosine phosphatase, Raf activation, glioblastoma, astrocytes, oncogenic Ras, therapeutic target, cell proliferation, tumor growth
- MeSH terms
- Animals, Cell Line, Female, Glioblastoma, Humans, Male, Mice, Inbred ICR, Phosphorylation, Oncogene Protein p21(ras), Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.